WARREN, NJ, USA I6, 2024 I PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing disease ...
LYON, France I6, 2024 I MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of ...
Portugal continues to strengthen its position as a leader in technological innovation with the development of the Amália AI ...
Study failed to meet primary and secondary efficacy endpoints - WARREN, N.J., Nov. 26, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced ...
Poor balance and coordination are prominent features of Friedreich’s ataxia (FRDA). Czech researchers found that neuropsychiatric symptoms are also common among patients with FRDA.
GlobalData on MSN19h
PTC Therapeutics ALS drug fails to meet endpoints as trials shut downNew Jersey-based biopharma, PTC Therapeutics said its Phase II trial of utreloxastat for patients with amyotrophic lateral ...
Bank of America Securities analyst Tazeen Ahmad maintained a Sell rating on PTC Therapeutics (PTCT – Research Report) yesterday and set a price ...
Widetrial is supporting an expanded access program (EAP) to bring MN-166 (ibudilast) to ALS patients ineligible for clinical ...
Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect ...
PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...
But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show whether twice-daily oral dosing ...
StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Free Report) (TSE:AEZ) in a report published on Sunday morning. The firm issued a sell rating on the biopharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback